Strategic group of experts (SAGE) on immunization
April 2013
"Initiating and then completing OPV2 withdrawal as soon as feasible is essential to: reduce the disease burden caused by circulating vaccine-derived poliovirus; avoid global programme fatigue and control programme cost; shorten the overall timeline towards the GPEI goal through the sequential removal of Sabin strains in order to boost global immunity against the remaining wild virus serotypes; and, potentially, to accelerate wild virus eradication in any areas of residual transmission." |
November 2012
"SAGE recommended that all countries should introduce at least 1 dose of IPV in their routine immunization programme to mitigate the risks associated with the withdrawal of OPV2. SAGE accepted the detailed scientific evidence presented to illustrate the risk-mitigating benefits of IPV use in the context of OPV2 withdrawal, specifically the evidence to show that, following OPV2 withdrawal, IPV vaccination will help to: (i) prevent poliomyelitis in IPV vaccinated individuals exposed to vaccine-derived poliovirus type-2 (VDPV2) or wild poliovirus type-2 (WPV2) (ii) improve the response to monovalent OPV type-1 (mOPV1) or an additional dose of IPV in a type 2 polio outbreak (iii) reduce the transmission of a reintroduced type 2 poliovirus (iv) accelerate wild poliovirus eradication by boosting immunity to wild poliovirus types 1 and 3." |
"SAGE recommended that all countries should introduce at least 1 dose of IPV in their routine immunization programme" |